Intra-Cellular Therapies Inc., of New York, said it presented at the Clinical Trials on Alzheimer's Disease conference additional results from ITI-007-200, a phase I/II trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects (part 1) and in patients with dementia, including Alzheimer's disease (part 2).